Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $59.60

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $61.33.

JANX has been the subject of a number of research analyst reports. BTIG Research initiated coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target for the company. Bank of America upped their price objective on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Wedbush reaffirmed an “outperform” rating and set a $53.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 11th. Cantor Fitzgerald began coverage on shares of Janux Therapeutics in a research note on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Jonestrading began coverage on shares of Janux Therapeutics in a research note on Tuesday. They set a “buy” rating and a $70.00 price objective for the company.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently made changes to their positions in the business. Barclays PLC increased its holdings in shares of Janux Therapeutics by 227.1% in the 3rd quarter. Barclays PLC now owns 17,922 shares of the company’s stock valued at $181,000 after purchasing an additional 12,443 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Janux Therapeutics in the fourth quarter worth approximately $57,000. FMR LLC increased its holdings in Janux Therapeutics by 25.5% in the third quarter. FMR LLC now owns 6,351,322 shares of the company’s stock worth $64,021,000 after buying an additional 1,288,526 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Janux Therapeutics by 27.8% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $11,592,000 after buying an additional 250,000 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in Janux Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock worth $152,000 after buying an additional 3,602 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 5.1 %

Shares of Janux Therapeutics stock opened at $47.96 on Monday. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -35.79 and a beta of 4.18. The business has a fifty day simple moving average of $33.62 and a 200-day simple moving average of $17.61. Janux Therapeutics has a fifty-two week low of $5.65 and a fifty-two week high of $58.69.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The firm had revenue of $2.46 million for the quarter, compared to analysts’ expectations of $0.98 million. Analysts anticipate that Janux Therapeutics will post -1.41 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.